Our Dedicated Team
EXECUTIVE OFFICERS
Dr. Michael Myers
Co-Founder, Chairman, Chief
Executive Officer and Director
Executive Officer and Director
Denise Carter
Co Founder, Chief Operating
Officer and Director
Sally Lawlor
Chief Financial Officer
BOARD OF DIRECTORS
SCIENTIFIC ADVISORS
Our Global Partners:
Rare diseases are only rare if you don’t live with one.®
Subscribe to Email Alerts
Sign up for alerts to stay up to date on Quoin Pharmaceuticals.
Latest News:
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if Approved Orphan Drug...
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin...